Meet the consortium

Biostrike is a global biotechnology company focused on finding and transforming innovative concepts into healthcare solutions. We have gathered world-class experts to help our clients achieve their goals by translating their technology concepts into healthcare solutions to reach patients faster. We are a reliable partner to our clients, and we build our business relationships on scientific excellence, medical need, and regulatory intelligence. Since the beginning of product ideation, the focus is on patient needs. Our medical and marketing expertise will support the medical device product development program, so your product will reach patients through an adequate development strategy. Biostrike brings its years of expertise, and reputation with faster, better, smarter services, meeting the needs and expectations of current and prospective clients

The i3S is a Research Unit resulting from a consortium between IBMC, INEB, IPATIMUP, and UPORTO, creating an environment of real breakthrough research and translation of discoveries into the clinic. i3S is dedicated to research and innovation in basic, applied,
and translational Health and Life sciences. It focuses on 3 research programs addressing major challenges such as cancer, infectious diseases, neurologic disorders, and regenerative medicine. The transdisciplinary nature of the programs allows us to address questions on the molecular and cellular basis of living systems, mechanisms underlying disease, and the development of novel tools for screening, diagnostic and therapeutic strategies. i3S has 74 research groups, more than 900 researchers, publishes about 650 papers a year, has 3 Clinical and Diagnostic platforms that provide cancer, SARS-CoV-2, and neurodegenerative diseases clinical services to the community, 25 active patents, about 100 national and international ongoing projects, and 13 scientific platforms, which provide access to advanced equipment for research in several fields (www.i3s.up.pt/ scientific-platforms). i3S has several transversal units that assure all management, financial, and communication aspects to successfully implement R&D projects. Furthermore, i3S fosters continuous advanced training for scientists and implements annual educational and outreach activities to close the gap between science and society.

Karolinska Institutet is one of the world’s leading medical universities with the vision of advancing knowledge about life and striving toward better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. Among many departments, The Department of Medicine, Solna (MedS) is one of the largest departments at Karolinska Institutet. The core activities of the Department of Medicine are clinical and undergraduate education for medical as well as biomedical students, post-graduate education, including at present 200 registered Ph.D. students, and research in different areas of biomedicine. The department conducts research in a large number of areas. The research groups are located at the Karolinska University Hospital in Solna. The proximity to patients is one of the department’s strengths. Conducting research in a clinical environment gives excellent opportunities to integrate basic research and patient-centered research. The research groups are linked to the department’s twelve research units, which also correspond to our main research areas ranging from dermatology to infectious diseases.

Kinetikos Health is a Portuguese e-health company expert in quantifying and classifying human movement. In the last decade, Kinetikos Health developed powerful and unique algorithms to instantly translate patients’ data into clinical insight for objective, accurate, and remote support in managing Parkinson’s Disease. Kinetikos Health has two evidence based products: a clinical platform for healthcare providers and a smartphone app that continuously collects and processes objective movement data, symptomatology, and medication adherence. This helps clinicians and patients better manage the condition, increasing patient outcomes and efficiency. Our portfolio of competencies spreads through artificial intelligence algorithms, data science, web- and mobile-based solutions,
biomechanics, user experience and engagement, data security, regulatory aspects, business development and sales, innovation management, and funding.

The Centre Hospitalier Universitaire Vaudois (CHUV) is one of the five university Hospitals in Switzerland. Collaborating with the Faculty of Biology and Medicine of the University of Lausanne (UNIL) and the Ecole Polytechnique Fédérale de Lausanne (EPFL), the CHUV plays a leading role in medical care, medical research, and education. The Department of Clinical Neurosciences (DNC), led by Prof. Philippe Ryvlin, includes the services of neurology, neurosurgery, neuropsychology and neurorehabilitation, spinal surgery, as well as the Leenaards Memory Center, and the Neuroscience Research Center. With around 500 employees, the DNC offers integrated and personalized care to patients suffering from diseases of the central and peripheral nervous system and is particularly active in the field of research and therapeutic innovations.

The Danish Epilepsy Centre (DEC) is a not-for-profit organization that is a part of the Danish healthcare system. It is the only tertiary referral center for patients with epilepsy in Denmark, where comprehensive medical assistance is offered to the patients, ranging from diagnostics to treatment, rehabilitation, and social integration. Clinical Neurophysiology is one of the most productive departments concerning research and development. The main emphasis has been electromagnetic signal analysis, seizure detection, epilepsy surgery, and video-EEG monitoring. The department in which the clinical study will be conducted has a state-of-the-art, dedicated Epilepsy Monitoring Unit with 4 beds. Both Filadelfia and CHUV have already 2 ongoing well-functioning collaborations in clinical studies (SEVERITY and PEDESITE studies) and collaborate within the European Reference Network EpiCARE.

The Institute of Molecular and Cellular Pharmacology (IPMC) is a multi-thematic institute of the French National Center for Scientific Research (CNRS), the largest public research organization in France, and of the University Côte d’Azur (UCA). It is located in the technology park of Sophia Antipolis, in the Nice area (French Riviera). The group of Massimo Mantegazza has established expertise in the study of the pathophysiology of neuronal excitability involved in neurologic and psychiatric diseases, in particular of models of genetic epilepsy. The group uses a variety of techniques performing in vitro, ex vivo, and in vivo investigations for identifying pathological mechanisms and therapeutic approaches.